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Whilst enthesitis, dactylitis and nail involvement are recognized as important outcomes of 
psoriatic arthritis (PsA) in the core set of domains in PsA,[1,2] it is still unclear how these 
outcomes should best be measured.[1,2] We systematically reviewed the instruments and 
the cutoffs used to report state or improvement, for enthesitis, dactylitis and nail involvement 
in recent randomised controlled trials (RCTs) in PsA.  
A systematic literature review of RCTs on any pharmacological intervention in patients with 
PsA was conducted to inform the EULAR recommendations for the management of PsA, by 
searching Medline, Embase and Cochrane datasets for the period 2010-2015.[3,4] Only 
published papers and only results of the placebo-controlled phases were analysed. The 
presence and type of all outcome measures reflecting enthesitis, dactylitis and nail 
involvement were collected. Cutoffs used for each measure (either as state or change, 
absolute or relative) were also collected. The proportion of trials in which each of the cutoffs 
for each measure was reported was calculated. 
Of 2,278 articles screened, 14 trials met the inclusion criteria: 4 (29%) reported on non-
biologic drugs (included targeted synthetic DMARDs, 1 trial), 5 (36%) on tumor necrosis 
factor inhibitors, 4 (29%) on other biologic modes of action and there was one strategy trial. 
The trials included a total of 4,744 patients. Four of the trials (29%) did not report any 
outcome on any of the 3 domains of interest (Table 1). Enthesitis and dactylitis outcomes 
were reported in the remaining 10 trials, while nail involvement was only reported in 3 trials 
(21%). These three outcomes have been measured in several different ways, none of which 
having been used in more than 3 trials (21%), and the majority of them was actually 
employed in only 1 (7%) or 2 (14%) trials. Different instruments have been used, different 
cutoffs and different statistics reported (e.g. mean and median improvement or resolution of 
the outcome, e.g. enthesitis score of zero) (Table 1). It was often the case that the same 
outcome measure was used (e.g. the Maastricht Ankylosing Spondylitis Enthesitis Score 
(MASES)), but then reported in such different ways (e.g. percentage of change, 
percentage1, percentage of improvement in one tendon/ligament, etc), that the potential 
uniformity in the measures used got diluted (Table 1). There was also heterogeneity in the 
timing of report of the outcome measures across trials. 
In summary, there is substantial lack of uniformity in the measurement of enthesitis, dactylitis 
and nail involvement in recent clinical trials of PsA. A similar lack of uniformity had previous 
been described for patient reported outcomes in PsA,[5,6] and in what concerns enthesitis, 
dactylitis and nail involvement measurement is the heterogeneity even larger. This relates to 
both the instruments used and the evaluation and interpretation of the results. An important 
aspect that requires attention are the ways in which the data are reported, namely the cutoffs 
chosen or the different statistics reported, which make the heterogeneity larger, even when 
one single outcome measure (see the example of MASES) is being used. Assessment of 
dactylitis and enthesitis needs further development taking both their resolution and 
appearance into account. Another methodological aspect deserving attention is the fact that 
these outcomes are actually only investigated in patients with active involvement at baseline, 
which violatest he principle of intention to treat analysis. Consensus is necessary and more 
elegant solutions should be considered. An update of the PsA Core Set of domains has just 
been published, however, without any indication of the instruments and cutoffs to be used.[2] 
Harmonization of measures to be used in trials and possibly also clinical practice is desirable 










Table 1 - Outcome measures used in 14 recent trials in PsA 




 4 (29%) 
Enthesitis 
Absolute change in 
enthesitis score 
Change (mean) in Leeds enthesitis index 2 (14%) 
Change (mean) in PsA modified MASES 3 (21%) 
Change (median) in MASES 1 (7%) 
Relative change 
(%) in enthesitis 
score 













MASES =0 (0-13) 1 (7%) 
Leeds enthesitis index =0 (0-6) 1 (7%) 
Enthesitis score =0 (0-4)* 1 (7%) 
Dactylitis 
Absolute change in 
dactylitis score 
Change (mean) in Dactylitis score (0-20)§ 2 (14%) 
Change (median) in Dactylitis score (0-20) 1 (7%) 
Change (median) in Leeds dactylitis index (0-60) 2 (14%) 
Change (mean) in Leeds dactylitis index (0-60) 2 (14%) 
Relative change 
(%) in dactylitis 
score 




Leeds dactylitis index (0-60) 1  2 (14%) 
Resolution of 
dactylitis 
Dactylitis score =0 (0-20) 3 (21%) 
Nail 
involvement 
Absolute change in 
score of nail 
involvement 
Change (mean) in modified Nail Psoriasis 
Severity Index 
1 (7%) 
Change (median) in modified Nail Psoriasis 
Severity Index 
1 (7%) 
Change (median) in Nail Psoriasis Severity Index 1 (7%) 
Relative change 
(%) in score of nail 
involvement 
% change in Nail Psoriasis Severity Index 1 (7%) 
PsA: psoriatic arthritis; MASES: Maastricht Ankylosing Spondylitis Enthesitis Score 
* Enthesitis score: 4-point enthesitis index to measure the presence (score of 1) or absence 
(score of 0) of tenderness at the lateral epicondyle humerus (lef tand right) and proximal 
achiles (left and right) 
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§ Dactylitis score: score of 1 for the presence of dactylitis and 0 for the absence in each digit 
(n=20), for an overall score ranging from 0 to 20 
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